[HTML][HTML] From empirical to pathogenesis-based treatments for psoriasis

PCM van de Kerkhof - Journal of Investigative Dermatology, 2022 - Elsevier
Journal of Investigative Dermatology, 2022Elsevier
Since the foundation of the European Society for Dermatological Research, pathogenesis of
psoriasis has been studied by many research groups, focusing on various compartments of
the skin. Understanding of the pathogenesis of psoriasis has evolved into a branching
model of innate and acquired immunity. Insights in the genetics of psoriasis proved to be
compatible with this model. Inspired by these insights, pathogenesis-based treatments have
emerged with unprecedented efficacy and sustainability. In particular, the cytokine network …
Since the foundation of the European Society for Dermatological Research, pathogenesis of psoriasis has been studied by many research groups, focusing on various compartments of the skin. Understanding of the pathogenesis of psoriasis has evolved into a branching model of innate and acquired immunity. Insights in the genetics of psoriasis proved to be compatible with this model.
Inspired by these insights, pathogenesis-based treatments have emerged with unprecedented efficacy and sustainability. In particular, the cytokine network harbors major treatment targets for biologics with TNF-α, the IL-17 family, IL-23 and, in the case of generalized pustular psoriasis, IL-36. Furthermore, the Jak TYK2, PDE-4, and AHR are targets for new small molecules in the treatment of psoriasis. Psoriasis research is a showcase par excellence of translational medicine, resulting in pathogenesis-based treatments.
Elsevier